PubMed HealthSearch

PubMed · 7346162

Oxidation and metabolic interconversion in malignant cachexia.

Abstract

Some patients with progressive malignant disease have an increase in basal metabolic expenditure as well as total caloric expenditure, but the findings are neither striking nor consistent. Studies of specific metabolic changes in such patients have shown the following. (a) The predominant substrate for energy in these subjects is fatty acid, as in normal humans. Comparative studies show, however, that greater proportions of the oxidative metabolism in patients with cancer are from fatty acids, particularly when exogenous glucose is available. While the free fatty acid levels in plasma decrease appropriately with glucose administration, current evidence suggests that the levels of free fatty acids themselves may not necessarily be directly related to the various disposal mechanisms. (b) Increased glycolysis and gluconeogenesis are present after overnight fasting in the patients with malignant disease, but these processes, which depend on liver metabolism, are appropriately suppressed with exogenous glucose. (c) Evidence is presented that leucine, an amino acid representative of branched-chain amino acids, is not under normal metabolic control in these subjects. For example, semistarvation does not result in diminished levels of branched-chain amino acids as it does in other patients. Also, glucose does not have its ordinary suppressive effect on branched-chain amino acid levels. Leucine turnover is increased in these patients as is the percentage of leucine flux which is oxidized. Limited data support the oxidation of this amino acid. All these data suggest that the peripheral effects of insulin and glucose may not be normally mediated in these subjects. They also suggest that amino acid metabolism and consequently protein metabolism may be unaffected by normal control factors in malignant disease.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Waterhouse. 1981. Oxidation and metabolic interconversion in malignant cachexia.. https://pubmed.ncbi.nlm.nih.gov/7346162/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Chimeric structural isomer fragments as cost-efficient internal standards for amino acid quantification by mass spectrometry.

Amino acid (AA) profiles from body fluids such as blood and urine are clinical indicators for diagnosing metabolic and hepatic diseases. Current quantitative methods, such as liquid chromatography-mass spectrometry (LC-MS) with isotopically labelled internal standards (ISs), are costly and technically demanding. This study proposes a cost-efficient alternative using structural isomers as ISs in a direct liquid infusion (DLI) tandem mass spectrometry (MS/MS) approach. The method leverages chimeric spectra and fragment intensity ratios to quantify AAs, demonstrating high linearity and precision even with a 3D ion trap mass analyser. This approach offers a viable strategy for AA quantification in preventive medicine, particularly for screening metabolic diseases such as phenylketonuria, diabetes, and liver dysfunction.

Amino Acids

Purification and structural characterization of a filamentous, mucin-like proteophosphoglycan secreted by Leishmania parasites.

Parasitic protozoa of the genus Leishmania secrete a filamentous macromolecule that forms networks and appears to be associated with cell aggregation. We report here the purification of this parasite antigen from Leishmania major culture supernatant and its compositional (75.6% carbohydrate, 20% phosphate, 4.4% amino acids, w/w), structural, and ultrastructural characterization as a highly unusual proteophosphoglycan (PPG). Mild acid hydrolysis, which cleaves preferentially hexose 1-phosphate bonds, releases the PPG glycans. Their structures are Galbeta1-4Man, Manalpha1-2Man, Galbeta1-3Galbeta1-4Man, PO4-6(Galbeta1-3)0-2Galbeta1-4Man, and PO4-6(Arabeta1-2Galbeta1-3)Galbeta1-4Man. These glycans are also components of the parasite glycolipid lipophosphoglycan, but their relative abundance and structural organization in PPG are different. Some of them represent novel forms of protein glycosylation. 31P NMR on native PPG demonstrates that phosphate is exclusively in phosphodiester bonds and that the basic structure R-Manalpha1-PO4-6-Gal-R connects the glycans. A phosphodiester linkage to phosphoserine (most likely R-Manalpha1-PO4-Ser) anchors the PPG oligosaccharides to the polypeptide. PPG has a unique amino acid composition; glycosylated phosphoserine (>43 mol %), serine, alanine, and proline account for more than 87 mol % and appear to be clustered in large proteinase-resistant domains. Electron microscopy of purified PPG reveals cable-like, flexible, long (to 6 microm), and unbranched filaments. The overall structure of PPG shows many similarities to mammalian mucins. Potential functions of this novel mucin-like molecule for the parasites are discussed.

Amino Acids

Role of oxoproline in the regulation of neutral amino acid transport across the blood-brain barrier.

Regulation of neutral amino acid transport was studied using isolated plasma membrane vesicles derived from the bovine blood-brain barrier. Neutral amino acids cross the blood-brain barrier by facilitative transport system L1, which may allow both desirable and undesirable amino acids to enter the brain. The sodium-dependent amino acid systems A and Bo,+ are located exclusively on abluminal membranes, in a position to pump unwanted amino acids out. gamma-Glutamyl transpeptidase, the first enzyme of the gamma-glutamyl cycle, is an integral protein of the luminal membrane of the blood-brain barrier. We demonstrate that oxoproline, an intracellular product of the gamma-glutamyl cycle, stimulates the sodium-dependent systems A and Bo,+ by 70 and 20%, respectively. Study of system A showed that 2 mM oxoproline increased the affinity for its specific substrate N-methylaminoisobutyrate by 50%. This relationship between the activity of the gamma-glutamyl cycle and system A transport may provide a short term regulatory mechanism by which the entry of potentially deleterious amino acids (i.e. neurotransmitters or their precursors) may be retarded and their removal from brain accelerated.

Amino Acids